Home » Stocks » CMPX

Compass Therapeutics, Inc. (CMPX)

Compass Therapeutics was planning to go public, but the IPO has been withdrawn.
Stock Price: $5.00 - $6.00
Current IPO price range
Market Cap 336.16M
Revenue (ttm) n/a
Net Income (ttm) -27.12M
Shares Out 61.12M
EPS (ttm) -0.44
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day n/a
Last Price n/a
Previous Close n/a
Change ($) n/a
Change (%) n/a
Day's Open n/a
Day's Range n/a
Day's Volume n/a
52-Week Range n/a

News

Hide News
TheStreet - 2 months ago

Cambridge, Massachusetts-based Compass was founded to develop antibody approaches to treating cancers as a monotherapy and in combination with existing approved drugs, including Her2+ breast c...

MarketWatch - 3 months ago

Compass Therapeutics Inc., the Massachusetts-based biopharmaceutical company focused on cancer treatments, has filed to go public.

SEC - 3 months ago

Compass Therapeutics, Inc. has filed to go public with an IPO on the NASDAQ stock exchange.

About CMPX

Compass Therapeutics is a clinical-stage biopharmaceutical company developing proprietary antibody therapeutics intended to engage the immune system to treat both solid tumors and hematological malignancies. Our immuno-oncology product candidates include a clinical-stage monoclonal antibody and a portfolio of bispecific antibodies. These product candidates are designed to address three critical components required for an effective immune response to cancer: induction of a potent innate immune response; activation of the adaptive immune system; ... [Read more...]

Industry
Biotechnology
IPO Date
Withdrawn
CEO
Thomas J. Schuetz
Employees
26
Stock Exchange
NASDAQ
Ticker Symbol
CMPX
Full Company Profile